Bio-Path stock: buy or sell?
May 14th, 2020
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused antisense drug development company in the United States.
Should I buy Bio-Path stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Following a trading plan helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, Bio-Path stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Bio-Path stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't detect any rating for BPTH stock for the last month.
Bio-Path stock analysis
Shares of Bio-Path slightly fell a bad -1.18% and closed at $5.02.
Shares of Bio-Path closed today at $5.02 and slightly fell a bad -1.18%. Since price and SMA50d lines crossed up on Friday, BPTH climbed $0.33 (7.04%).
After boosting a great 5.27% in a week last week, Bio-Path closed this week at $5.02 and raised a beatiful 1.83%. Late April BPTH plunged a dreadful -22.70% in just one week.
If you observe the weekly chart, price is in a simple uptrend, tested $4.35 level and now climbing back aiming its last top at $6.16. Early September BPTH price bounced up over the SMA of 40 weeks that acted as support stopping new slides.
Bio-Path stock price history
Bio-Path stock went public on March 15th, 2010 with a price of $100.001. Since then, BPTH stock declined a -95.00%, with a yearly average of -9.50%.
1: Adjusted price after possible price splits or reverse-splits.
Bio-Path stock historical price chart
BPTH stock reached 52-week highs at $19.00, and all-time highs 2014-01-03 with a price of 1050.
Bio-Path stock price targetNobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we have not found any price forecast for Bio-Path stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per Share, when Bio-Path posted its last earnings report, it . Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2017, Bio-Path annual sales boosted an amazing 184.62% to $0.04 million dollars from $0.01 marked in 2016. Similarly, its income margin (compared to sales) skyrocketed to -18,981.08%, that is $-7.02 million.
|2016||$0.01 M||-||$-6.75 M-51923.1%||-|
|2017||$0.04 M||184.62%||$-7.02 M-18981.1%||4.04%|
Quarterly financial resultsReported quarter earnings marked $-1.91 M with a profit margin of . Profit margin stayed steady a 0.00% compared to previous quarter when profit margin was inf%. When comparing sales to same quarter last year, Bio-Path sales marked a bloodcurdling loss and plunged a -100.00%. Looking back to recent quarterly results, Bio-Path posted 4 positive quarters in a row.
|2017-Q4||$0.04 M||-||$-2.17 M-5856.8%||-|
Bio-Path ownershipChecking Bio-Path ownership structure gives valuable information about the company and its governance (insider ownership) or the amount of investors that are on the short side.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Bio-Path, 1.26% of all outstanding shares are owned by its staff.
In case of Bio-Path stock, 11.43% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for BPTH stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Bio-Path:
|Market cap||$18.5 M|
|Total shares||3.7 M|
|Float shares||3.7 M|
|- Institutional holdings (%)||11.4%|
|- Insider holdings (%)||1.3%|
|Shares in short selling||0.0%|
|Thursday, May 14th, 2020|
|Day range||$4.69 - $5.10|
|Average true range||$0.40|
|50d mov avg||$4.69|
|100d mov avg||$5.80|
|200d mov avg||$8.14|
Bio-Path performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. For Bio-Path, the benchmark is made against .